The MSD for Mothers team recently returned from the World Economic Forum annual meeting in Davos, where we joined leaders from business, government, civil society and academia in discussions around the theme, “Creating a Shared Future in a Fractured World.” In keeping with the focus on the global economy, MSD for Mothers and our partners made the business case for investing in maternal health, argued for greater private sector involvement in innovative financing for development, and advocated for more research on the experiences of wome
Fortune Magazine has released its annual list of the World’s Most Admired Companies. For the first time, Merck ranked first among its peers for pioneering innovation and second overall among pharmaceutical industry in the survey.
“We are honored to be recognized on Fortune’s list of Most Admired Companies,” says Ken Frazier, chairman and CEO, Merck. “This ranking reflects our strategic focus and relentless passion for inventing new ways to save and improve lives.”
Dr. Julie L. Gerberding, M.D., M.P.H., Executive Vice President & Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health for Merck, has been named the Healthcare Businesswomen’s Association (HBA) 2018 Woman of the Year.
As 2017 draws to a close, we wanted to reflect and celebrate the progress we've made – alongside our partners and maternal health champions – toward creating a world where no woman dies while giving life. We can end preventable maternal deaths in our lifetime, but we can't do it alone. We want to thank all who have supported our initiative this year, from championing quality health for mothers across the globe, to partnering together to find inventive solutions to move the needle on this global challenge.
The Utkrisht Impact Bond – so named for the Hindi expression for ‘Excellence’ – is the world’s first health impact bond. It was developed by partners including USAID, Merck for Mothers, the UBS Optimus Foundation, PSI, Palladium, and HLFPPT.
Program Expanded to Reach Additional 100 Million People Annually for Lymphatic Filariasis in Support of New, Evidence-Based WHO Guidelines
KENILWORTH, N.J., November 30, 2017 /3BL Media/ -- Today, Merck announced an expansion of the MECTIZAN® Donation Program (MDP) to reach up to an additional 100 million people per year through 2025 as part of the global effort to eliminate lymphatic filariasis (LF).
by Mary-Ann Etiebet, Executive Director, Merck for Mothers
I keep thinking about Nour from Syria, who at age 22 discovered she was pregnant with her first child while running for her life. I think of how Nour spent her pregnancy: uncertain, undernourished, waiting things out in a cold tent at a refugee camp in Greece. I imagine her experiencing the pains of labor, and delivering her baby surrounded by strangers speaking a language she didn’t understand.